Granted Patent
B2
US 12,371,657 · App. 18/545,335 · Granted Jul 29, 2025
Cell culture media compositions for primary cells
C12N5/0037A61K35/19A61P17/02C12N5/0068C12N5/0662C12N5/069C12N5/0692C12N2500/84C12N2501/105C12N2501/11C12N2501/115C12N2501/165C12N2502/115C12N2533/50C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Platelet lysate compositions and cell culture media compositions for maintaining and/or growing mammalian cells, such as mammalian endothelial cells (ECs) and mammalian endothelial progenitor cells (EPCs), in particular human ECs (huECs) and human EPCs (huEPCs), such as primary huECs and primary huEPCs, are provided. The cell culture media compositions contain a basal medium, a platelet lysate and, optionally, one or more exogenously added growth factors. Also provided are methods for making and using such cell culture media compositions to grow and/or maintain ECs and EPCs, including huECs and huEPCs, as well as cell culture vessels, dishes, plates, and/or flasks pretreated with the cell culture media compositions.
Claims (16)
1. A wound healing composition comprising:
a lyophilized platelet lysate having 50% or less of water; and
a supplemental exogenous growth factor in a ratio of at least 100 to 1 or less per ng of growth factor in the platelet lysate.
2. The wound healing composition of claim 1 , further comprising an anticoagulant.
3. The wound healing composition of claim 2 , wherein the anticoagulant is selected from the group consisting of heparin, heparin derivatives, EDTA, citrate, oxalate, and combinations thereof.
4. The wound healing composition of claim 1 , further comprising about 0.1 mM to 100 mM calcium.
5. The wound healing composition of claim 1 , wherein the supplemental exogenous growth factor is FGF.
6. The wound healing composition of claim 1 , wherein the wound healing composition is free from bulking agents selected from the group consisting of sucrose, mannitol, trehalose, and combinations thereof.
7. The wound healing composition of claim 1 , wherein the wound healing composition is free from animal serum.
8. The wound healing composition of claim 1 , further comprising one or more selected from the group consisting of one or more amino acids, an energy source, one or more vitamins, one or more inorganic salts, and combinations thereof.
9. The wound healing composition of claim 1 , wherein the wound healing composition further comprises from about 200 to about 1600 mg/L amino acids, from about 20 to about 50 mg/L vitamins, from about 6000 to about 8000 mg/L inorganic salts, and from about 800 to about 3500 mg/L glucose.
10. The wound healing composition of claim 1 , further comprising glucose.
11. The wound healing composition of claim 1 , further comprising MCDB-131, DMEM/F-12, or EBM-2.
12. The wound healing composition of claim 1 , wherein the supplemental exogenous growth factor is fibroblast growth factor (FGF-B), epidermal growth factor (EGF), platelet derived growth factor (PDGF), insulin-like growth factor (IGF), transforming growth factor (TGF), vascular endothelial growth factor (VEGF), liver growth factor (LGF), bone morphogenetic protein (BMP), colony stimulating factor (CSF), hepatocyte growth factor (HGF), nerve growth factor (NGF), or combinations thereof.
13. The wound healing composition of claim 1 , wherein the lyophilized platelet lysate comprises a total protein concentration of at least 30 mg/ml.
14. A method of administering a wound healing composition, comprising applying the wound healing composition of claim 1 to a wound.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 19, 2023
From: DIETZ, ALLAN B.; KNUTSON, GAYLORD
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 065912/0982 →
Continuity (3)
Provisional Application
61994637
· May 16, 2014
References Cited (179)
US 5185160A
· Chao
· 1993
[cited by applicant]
US 5198357A
· Holmovist et al.
· 1993
[cited by applicant]
US 5292362A
· Bass et al.
· 1994
[cited by applicant]
US 5756686A
· Heldin et al.
· 1998
[cited by applicant]
US 5834418A
· Brazeau et al.
· 1998
[cited by applicant]
US 7335508B2
· Yayon et al.
· 2008
[cited by applicant]
US 8361796B2
· Menasche et al.
· 2013
[cited by applicant]
US 8501170B2
· Rebulla et al.
· 2013
[cited by applicant]
US 9682104B2
· Patel
· 2017
[cited by applicant]
US 20040151709A1
· Gorrochategui Barrueta et al.
· 2004
[cited by applicant]
US 20050214277A1
· Schaufler
· 2005
[cited by applicant]
US 20060014266A1
· Tomasevic et al.
· 2006
[cited by applicant]
US 20060142198A1
· Gandy
· 2006
[cited by applicant]
US 20070184029A1
· Mishra
· 2007
[cited by applicant]
US 20090023211A1
· Persson et al.
· 2009
[cited by applicant]
US 20090305401A1
· Strunk et al.
· 2009
[cited by applicant]
US 20100120144A1
· Mishra
· 2010
[cited by applicant]
US 20110123498A1
· Westenfelder
· 2011
[cited by applicant]
US 20110171731A1
· Dietz et al.
· 2011
[cited by applicant]
US 20140335195A1
· Houze et al.
· 2014
[cited by applicant]
US 20160074481A1
· Burnouf et al.
· 2016
[cited by applicant]
AU 2010202675A1
· 2011
[cited by examiner]
EP 2733200A1
· 2014
[cited by applicant]
WO 8910398A1
· 1989
[cited by applicant]
WO 9515763A1
· 1995
[cited by applicant]
WO 2005065419A2
· 2005
[cited by applicant]
WO 2006137778A1
· 2006
[cited by applicant]
WO 2008034803A1
· 2008
[cited by applicant]
WO 2008110570A1
· 2008
[cited by applicant]
WO 2009002811A2
· 2008
[cited by applicant]
WO 2009144718A1
· 2009
[cited by applicant]
WO 2010017216A2
· 2010
[cited by applicant]
WO 2010033605A2
· 2010
[cited by applicant]
WO 2010033605A3
· 2010
[cited by applicant]
WO 2013076507A2
· 2013
[cited by applicant]
WO 2013113024A1
· 2013
[cited by applicant]
WO 2016139340A1
· 2016
[cited by applicant]
WO 2016193591A1
· 2016
[cited by applicant]
U.S. Appl. No. 15/609,444 (Year: 2014).
[cited by examiner]
“Anticoagulant” https://en.wikipedia.org/wiki/Anticoagulant (Year: 2024).
[cited by examiner]
European Search Report for Application No. 09815127.7 mailed Dec. 13, 2012, 12 pages.
[cited by applicant]
European Search Report for Application No. 16170752.6 mailed Aug. 29, 2016.
[cited by applicant]
Extended European Search Report, EP Appln. No. 19181191.8, dated Nov. 26, 2019.
[cited by applicant]
Faler et al., “Transforming Growth Factor-β and Wound Healing,” Perspectives in Vascular Surgery and Endovascular Therapy, vol. 18, No. 1, pp. 55-62 (2006).
[cited by applicant]
Fan et al., “Glioma stem cells: evidence and limitation,” Semin Cancer Biol., 17(3):214-218 (2007).
[cited by applicant]
Frank et al., “Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes,” The Journal of Biological Chemistry, vol. 270, No. 21, pp. 12607-12613 (1995).
[cited by applicant]
Freeze-Drying/Lyophilization of Pharmaceutical and Biological Products, Marcel Dekker, Inc., New York, New York, edited by Louis Rey and Joan C. May, 488 pages (1999).
[cited by applicant]
Grounds of Appeal by Opponent for EP3095856 mailed Aug. 12, 2022.
[cited by applicant]
Gruber et al., “Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cells under in vitro conditions,” Platelets, 15(…
[cited by applicant]
Hara et al., “Platelets as a Source of Growth-Promoting Factors for Tumor Cells,” Cancer Research, vol. 40, pp. 1212-1216 (1980).
[cited by applicant]
Ho et al., “The behavior of human mesenchymal stem cells in 3D fibrin clots: dependence on fibrinogen concentration and clot structure,” Tissue Eng., 12(6):1587-1595 (2006).
[cited by applicant]
Hoffbauer et al., “Human platelet lysate is a a feasible candidate to replace fetal calf serum as medium supplement for blood vascular and lymphatic endothelial cells,” International Society for Cellular Therapy, (2017).
[cited by applicant]
Ihm et al., “Effects of mixed leukocyte reaction, hydrocortisone and cyclosporine on expression of leukocyte adhesion molecules by endothelial and mesangial cells,” J Korean Med Sci., 11(6):495-500 (Dec. 1996).
[cited by applicant]
International Preliminary Report on Patentability for PCT/US2009/057170, mailed Mar. 31, 2011, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability for PCT/US2015/030834 mailed Nov. 22, 2016, 12 pages.
[cited by applicant]
International Search Report (partial) for corresponding PCT Patent Application No. PCT/US2015/030834 mailed Jul. 31, 2015.
[cited by applicant]
International Search Report (partial) for corresponding PCT Patent Application No. PCT/US2015/030834 mailed Oct. 19, 2015.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2015/030834 mailed Oct. 19, 2015.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2009/057170, mailed May 10, 2010, 12 pages.
[cited by applicant]
Janetzko et al., “Fully automated processing of buffy-coat-derived pooled platelet concentrates,” Transfusion, vol. 44, pp. 1052-1058 (2004).
[cited by applicant]
Janowska-Wieczorek et al., “Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer,” Int J Cancer., 113(5):752-760 (2005).
[cited by applicant]
Janowska-Wieczorek et al., “Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells,” Transfusion, 46(7):1199-1209 (Jul. 2006).
[cited by applicant]
Jung et al., “Ex vivo expansion of human mesenchymal stem cells in defined serum-free media,” Stem Cells Int., 2012:123030, 21 pgs (May 7, 2012).
[cited by applicant]
Kitange et al., “Recent advances in the molecular genetics of primary gliomas,” Curr Opin Oncol., 15(3):197-203 (2003).
[cited by applicant]
Kocaoemer et al., “Human AB Serum and Thrombin-Activated Platelet-Rich Plasma are Suitable Alternatives to Fetal Calf Serum for the Expansion of Mesenchymal Stem Cells from Adipose Tissue,” Stem Cells, vol. 25, pp. 1270…
[cited by applicant]
Labitzke et al., “A serum-free medium formulation supporting growth of human umbilical cord vein endothelial cells in long-term cultivation,” Cytotechnology, 35(2):87-92 (Mar. 2001).
[cited by applicant]
Lange et al., “Platelet lysate for rapid expansion of human mesenchymal stromal cells,” Cell Ther Transplant., 1 (2):49-53 (2008).
[cited by applicant]
Le Bras et al., “Fibroblast Growth Factor 2 Promotes Pancreatic Epithelial Cell Proliferation Via Functional Fibroblast Growth Factor Receptors During Embryonic Life,” Diabetes, vol. 47, pp. 1236-1242 (1998).
[cited by applicant]
Lee et al., “Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines,” Cancer Cell, 9(5):391-403 (2006).
[cited by applicant]
Lindroos et al., “Differential gene expression in adipose stem cells cultured in allogeneic human serum versus fetal bovine serum,” Tissue Eng Part A., 16(7):2281-2294 (Jul. 2010).
[cited by applicant]
Linkhart et al., “Growth Factors for Bone Growth and Repair: IGF, TGFβ and BMP,” Bone, vol. 19, No. 1, Supplement, pp. 1S-12S (Jul. 1996).
[cited by applicant]
Lucarelli et al., “Platelet-derived growth factors enhance proliferation of human stromal stem cells,” Biomaterials, 24(18):3095-3100 (2003).
[cited by applicant]
Macopharma, “Testing of platelet lysate derived from platelet concentrate” MacoProductions (Apr. 2, 2009).
[cited by applicant]
Mariluz et al., “Serum-converted platelet lysate can substitute for fetal bovine serum in human mesenchymal stromal cell cultures,” Cyrotherapy (2013), 15, pp. 1458-1468.
[cited by applicant]
Marquez-Curtis et al., “Microvesicles derived from activated platelets enhance the invasive potential of breast cancer cells,” Blood (ASH Annual Meeting Abstracts) 104: Abstract 3904 (2004).
[cited by applicant]
Martineau et al., “Effects of calcium and thrombin on growth factor release from platelet concentrates: kinetics and regulation of endothelial cell proliferation,” Biomaterials, 25(18):4489-4502 (2004).
[cited by applicant]
Minutes and Interloctury Decision with Enclosures for Application No. 09815127.7 mailed Dec. 6, 2018.
[cited by applicant]
Minutes of Oral Proceedings for EP3095856 mailed Mar. 30, 2022.
[cited by applicant]
Mojica-Henshaw et al., “Serum-converted platelet lysate can substitute for fetal bovine serum in human mesenchymal stromal cell cultures,” Cyrotherapy, 15, pp. 1458-1468 (2013).
[cited by applicant]
Naaijkens et al., “Human platelet lysate as a fetal bovine serum substitute improves human adipose-derived stromal cell culture for future cardiac repair applications,” Cell Tissue Res., 348(1):119-130, Epub (Mar. 7, 20…
[cited by applicant]
Ogawa et al., “Production of macromolecular activators of phagocytosis by lysed platelets,” Thromb Res., 97(5):297-306 (2000).
[cited by applicant]
Piccirillo et al., “Brain tumour stem cells: possibilities of new therapeutic strategies,” Expert Opin Biol Ther., 7 (8):1129-1135 (2007).
[cited by applicant]
Preliminary Opinion of the Board of Appeal for 3095856 mailed Dec. 8, 2023.
[cited by applicant]
Protein Complex, Wikipedia, https://en.wikipedia.org/wiki/Protein_complex, 6 pages (Aug. 11, 2019).
[cited by applicant]
Proulx et al., “Optimization of culture conditions for porcine corneal endothelial cells,” Mol Vis., 13:524-533 (Apr. 3, 2007).
[cited by applicant]
Ranzato et al., “Platelet lysate Stimulates Wound Repair of HaCaT keratinocytes,” British Journal of Dermatology, vol. 159, pp. 537-545 (2008).
[cited by applicant]
Rauch et al., “Alternatives to the Use of Fetal Bovine Serum: Human Platelet Lysates as a Serum Substitute in Cell Culture Media” Division of Physiology, Innsbruck Medical University, Innsbruck, Austria; Central Institu…
[cited by applicant]
Reddoch et al., Hemostatic Function of Apheresis Platelets Stored at 4C and 22C, Shock, vol. 41, Supplement 1, p. 54-61 (2014).
[cited by applicant]
Reply Brief of Maco Pharma in the opposition of EP2334785, dated Oct. 20, 2017.
[cited by applicant]
Reply of Maco Pharma to the Summons to Oral Proceedings of EP3095856 mailed Apr. 30, 2021.
[cited by applicant]
Extended European Search Report for Application No. 24151761.4 mailed May 2, 2024.
[cited by applicant]
Acid-base homeosttasis, Wikipedia, https://en.wikipedia.org/wiki/Acid-base_homeostasis, 7 pages (Jan. 2, 2020).
[cited by applicant]
Anitua et al., “Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture,” Journal of Orthopaedic Research, vol. 23, pp. 281-297 (2005).
[cited by applicant]
Arora, “Cell Culture Media: A Review,” Mater Methods, 3:175 (2013).
[cited by applicant]
Attachment to Brief in Opposition of EP2334785 entitled Testing of Platelet Lysate Derived from Platelet Concentrate (Apr. 2, 2009), filed by Maco Pharma, dated Feb. 24, 2017 (french/english version attached).
[cited by applicant]
Australian Examination Report for Application No. 2015259094 mailed Aug. 21, 2020.
[cited by applicant]
Australian Examination Report No. 2 for Application No. 2015259094 mailed May 11, 2021.
[cited by applicant]
Australian Examination Report No. 2 for Application No. 2021277734 mailed Dec. 22, 2022.
[cited by applicant]
Barano et al., “Serum-Free Medium Enhances Growth and Differentiation of Cultured Pig Granulosa Cells,” Endocrinology, vol. 116, No. 1, pp. 51-58 (1985).
[cited by applicant]
Barsotti et al., “Effect of platelet lysate on human cells involved in different phases of wound healing,” PLoS One, 8 (12):e84753 (Dec. 27, 2013).
[cited by applicant]
Bates et al., “The Role of Vascular Endothelial Growth Factor in Wound Healing,” Lower Extremity Wounds, vol. 2, No. 2, pp. 107-120 (2003).
[cited by applicant]
Bernardi et al., “The production method affects the efficacy of platelet derivatives to expand mesenchymal stromal cells in vitro,” J. Tarnsl. Med. 15:90, 10 pages (2017).
[cited by applicant]
Bernardo et al., “Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute,” J. of Cell. Physiol., 2…
[cited by applicant]
Bieback et al., “Clinical Protocols for the Isolation and Expansion of Mesenchymal Stromal Cells,” Transfus Medicine and Hemotherapy, vol. 35, pp. 286-294 (2008).
[cited by applicant]
Brief in Opposition of EP2334785, filed by Maco Pharma, dated Feb. 24, 2017 (french/english version attached).
[cited by applicant]
Brief in Opposition of EP3095856, filed by Maco Pharma mailed May 13, 2020 (french/english version attached).
[cited by applicant]
Brindley et al., “Peak serum: implications of serum supply for cell therapy manufacturing,” Regen Med., 7(1):7-13 (Jan. 2012).
[cited by applicant]
Brunner et al., “Serum-free Cell Culture: The Serum-free Media Interactive Online Database,” Altex, 27(1):53-62 (2010).
[cited by applicant]
Canadian Examination Report for Application No. 2,949,225 mailed May 18, 2021.
[cited by applicant]
Canadian Examination Report for Application No. 2,949,225 mailed Jun. 8, 2022.
[cited by applicant]
Canadian Examination Report for Application No. 2,949,225 mailed Aug. 18, 2023.
[cited by applicant]
Canadian Examination Report for Application No. 3,138,143 mailed Dec. 1, 2022.
[cited by applicant]
Capelli et al., “Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts,” Bone Marrow Transplant., 40(8):7…
[cited by applicant]
Carrancio et al., “Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification,” Experimental Menatology, vol. 36, pp. 1014-1021 (2008).
[cited by applicant]
Chase et al., “A novel serum-free medium for the expansion of human mesenchymal stem cells,” Stem Cell Res Ther., 1(1):8, (Apr. 2, 2010).
[cited by applicant]
Cohen et al., “Insulin-Like Growth Factors (IGFs), IGF Receptors, and IGF-Binding Proteins in Primary Cultures of Prostate Epithelial Cells,” Journal of Clinical Endocrinology and Metabolism, vol. 73, No. 2, pp. 401-407…
[cited by applicant]
Communication of a notice of opposition of EP2334785, dated Mar. 13, 2017.
[cited by applicant]
Communication of a notice of opposition of EP3095856 mailed May 19, 2020.
[cited by applicant]
Communication pursuant to Rule 114(2) EPC, enclosing Third party observations, dated Apr. 25, 2018.
[cited by applicant]
Communication pursuant to Rule 114(2) EPC, enclosing Third party observations for Application No. 09815127.7 mailed Sep. 1, 2015.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC, regarding EP Application No. 09815127.7 mailed Mar. 17, 2015.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC, regarding EP Application No. 09815127.7 mailed May 29, 2015.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC, regarding EP Application No. 09815127.7 mailed Nov. 10, 2015.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC, regarding EP Application No. 16170752.6 mailed Jul. 20, 2017.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC, regarding EP Application No. 15729597.3, dated Jul. 10, 2018.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC, regarding EP Application No. 15729597.3, dated Mar. 20, 2020.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC, regarding EP Application No. 19181191.8 mailed Mar. 16, 2021.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC, regarding EP Application No. 15729597.3 mailed Aug. 10, 2021.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC, regarding EP Application No. 19181191.8 mailed Mar. 28, 2022.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC, regarding EP Application No. 19181191.8 mailed Apr. 19, 2023.
[cited by applicant]
Communication Regarding Oral Proceedings for Application No. 15729597.3 mailed Jul. 31, 2023.
[cited by applicant]
Cowan et al., “Stimulation of human tumor colony formation by platelet lysate,” J. Lab. Clin. Med., vol. 102, No. 6, pp. 973-986 (1983).
[cited by applicant]
Crespo-Diaz et al., “Platelet Lysate Consisting of a Natural Repair Proteome Supports Human Mesenchymal Stem Cell Proliferation and Chromosomal Stability,” Cell Transplantation, vol. 20, pp. 797-811 (2011).
[cited by applicant]
Cryocheck, “Platelet Lysate” Intended use and instruction sheet; 1 page. Printed on Oct. 26, 2014 from Cryopep website at http://cryopep.com/cryocheck-platelet-lysate/.
[cited by applicant]
Decision Rejecting the Opposition Against EP3095856 mailed Mar. 30, 2022.
[cited by applicant]
Dietz et al., “A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers,” Transfusion, 46(12):2083-2089 (2006).
[cited by applicant]
Doucet et al., “Platelet Lysates Promote Mesenchymal Stem Cell Expansion: A Safety Substitute for Animal Serum in Cell-Based Therapy Applications,” Journal of Cellular Physiology, 205:228-236 (2005).
[cited by applicant]
Eastment et al., “Platelet Derived Growth Factor(s) for a Hormone-responsive Rat Mammary Tumor Cell Line,” Journal of Cullular Physiology, vol. 97, No. 1, pp. 17-28 (1978).
[cited by applicant]
EDQM, “Guide to the preparation, use and quality assurance of Blood Components,” European Committee (Partial Agreement on Blood Transfusion (CD-P-TS), 2015).
[cited by applicant]
“EGM-2 Endothelial Cell Growth Medium-2 BulletKit” Pharma & Biotech, retriefed from the Internet: https://bioscience.lonza.com/lonza_bs/en/Primary--Stem-Cells/p/000000000000185303/EGM-2-Endothelial-Cell-Growth-Medium-2-…
[cited by applicant]
EPO Communication forwarding Opponent's Submission Reply for EP3095856 mailed Jun. 6, 2023.
[cited by applicant]
Canadian Examination Report for Application No. 3,138,143 mailed Apr. 26, 2024.
[cited by applicant]
Horsch et al., “Evaluation of basal membrane-derived and biomaterial matrices for endothelial cell expansion and maintenance of their primitive potentialm,” Journal of Stem Cells and Regenerative Medicine, vol. 6, No. 2…
[cited by applicant]
Leotot et al., “Platelet lysate coating on scaffolds directly and indirectly enhances cell migration, improving bone and blood vessel formation,” Acta Biomaterialia, vol. 9, pp. 6630-6640 (2013).
[cited by applicant]
Walenda et al., “Human Platelet Lysate Gel Provides a Novel Three Dimensional-Matrix for Enhanced Culture Expansion of Mesenchymal Stromal Cells,” Tissue Engineering: Part C, vol. 18, No. 12, pp. 924-934, DOI: 10.1089/t…
[cited by applicant]
Reply to Observations made by the Patent Proprieter in EP3095856 mailed Jul. 30, 2021.
[cited by applicant]
Reply to the Grounds of Appeal by Proprietor for EP3095856 including Auxiliary Requests mailed Dec. 13, 2022.
[cited by applicant]
Response to Preliminary Opinion for EP3095856 mailed Feb. 23, 2024.
[cited by applicant]
Saline (medicine), Wikipedia, https://en.wikipedia.org/wiki/Saline_(medicine), 8 pages (Dec. 30, 2019).
[cited by applicant]
Schallmoser et al., “Generation of a pool of human platelet lysate and efficient use in cell culture,” Methods Mol Biol., 946:349-62 (2013).
[cited by applicant]
Sell et al., “Incorporating Platelet-Rich Plasma into Electrospun Scaffolds for Tissue Engineering Applications”; Tissue Engineering: Part A; 17(21-22):2723-2737 (Nov. 1, 2011).
[cited by applicant]
Selvaggi et al., “Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions,” Blood, 89(3):776-779 (Feb. 1, 1997).
[cited by applicant]
Singh et al., “Identification of a cancer stem cell in human brain tumors,” Cancer Res., 63(18):5821-5828 (2003).
[cited by applicant]
Stacey et al., “Randomised Double-blind Placebo Controlled Trial of Topical Autologous Platelet Lysate in Venous Ulcer Healing,” Eur. J. Vasc. Endovasc. Surg., vol. 20, pp. 296-301 (2000).
[cited by applicant]
Submission in Response to Opponent Submission of Apr. 26, 2021 of EP3095856 mailed Jun. 1, 2021.
[cited by applicant]
Submission by Opponent in Reply to last submission of Jun. 1, 2021 for EP3095856 mailed Jul. 30, 2021.
[cited by applicant]
Submission in Reply to notice of opposition of EP2334785 with accompanying auxiliary requests, dated Aug. 9, 2017.
[cited by applicant]
Submission in Reply to notice of opposition of EP3095856 with accompanying auxiliary requests dated Oct. 19, 2020.
[cited by applicant]
Submission in Response to Summons to Attend Oral Proceedings, EP Appln. No. 09 815 127.7, dated Aug. 10, 2018.
[cited by applicant]
Summons to attend oral proceedings regarding opposition of EP2334785, dated Dec. 20, 2017.
[cited by applicant]
Summons to attend oral proceedings for Application No. 15729597.3 mailed Apr. 11, 2023.
[cited by applicant]
Summons to attend oral proceedings regarding opposition of EP3095856 mailed Apr. 7, 2021.
[cited by applicant]
Swope et al., “Long-Term Proliferation of Human Melanocytes is Supported by the Physiologic Mitogens α-Melanotropin, Endothelin-1, and Basic Fibroblast Growth Factor,” Experimental Cell Research, vol. 217, pp. 453-459 (…
[cited by applicant]
Tekkatte et al., ‘Humanized’ stem cell culture techniques: the animal serum controversy, Stem Cells Int., 2011:504723, Epub (Apr. 3, 2011).
[cited by applicant]
Vogel et al., “Platelet-rich plasma improves expansion of human mesenchymal stem cells and retains differentiation capacity and in vivo bone formation in calcium phosphate ceramics,” Platelets, 17(7):462-469 (Nov. 2006).
[cited by applicant]
Wang, “Lyophilization and development of solid protein pharmaceuticals,” Int J Pharm. ; 203(1-2): 1-60 (Aug. 2000).
[cited by applicant]
Wang et al., “Platelet-induced inhibition of tumor cell growth,” Thromb Res., 123:324-330 (2008).
[cited by applicant]
Weibrich et al., “Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count,” J Craniomaxillofac Surg., 30:97-102 (2002).
[cited by applicant]
WHO Technical Report, Series 924, 75 pages (2004).
[cited by applicant]
Willey et al., Bombesin and the C-Terminal Tetradecapeptide of Gastrin-releasing Peptide are Growth Factors for Normal Human Bronchial Epithelial Cells, Experimental Cell Research, vol. 153, pp. 245-248 (1984).
[cited by applicant]
Zimmermann et al., “Different preparation methods to obtain platelet components as a source of growth factors for local application,” Transfusion, vol. 41, pp. 1217-1224 (2001).
[cited by applicant]
Cited By (1)